POSITION: Characterising risk factors and outcomes in patients (pts) with stage III unresectable non-small cell lung cancer (uNSCLC) who fail to complete concurrent chemoradiotherapy (cCRT) or progress during or shortly after cCRT
Loading...
Contact
Check for full-text access
Issue Date
Type
Conference Proceedings
Language
Keywords
Alternative Title
Abstract
Background: PACIFIC established consolidation durvalumab as standard of care for pts with Stage III uNSCLC and no progression after complete cCRT. POSITION aims to identify factors associated with failure to complete cCRT and progression during or shortly after cCRT.
Description
Citation
Publisher
License
Journal
ESMO Open
Volume
Issue
20-23